DOI: 10.36347/sjmcr.2024.v12i04.025

Pages: 476-483

Hemophilia A is a hemorrhagic disorder caused by a deficiency in factor VIII coagulation. Its incidence is 1 to 2 per 10,000 male births. Hemophilia A is characterized by intra-articular, mucosal, or cutaneous bleeding, and its management relies on the substitution of factor VIII with plasma derived or recombinant products. However, the major complication of treatment is the development of anti-factor VIII inhibitors, rendering substitution therapy ineffective. The aim of this study is to investigate the prevalence of anti-factor VIII inhibitors, the severity of hemophilia, and the follow-up of hemophilia patients developing anti-FVIII inhibitors in a hemophiliac population by presenting their epidemiological and biological characteristics. We conducted a retrospective descriptive cross-sectional study at the Central Hematology Laboratory of the Ibn Sina Hospital Center in Rabat (Morocco) over a period of 37 months, from December 1, 2020, to December 31, 2023. The study included 172 hemophilia A patient, with a mean age of 25 years. 55 patients developed anti-FVIII inhibitors (32%). The majority of positive inhibitor hemophiliacs were severe hemophiliacs (87%), including 23 cases of low responders (42%) and 32 cases of high responders (58%). The results obtained partly agree with most national studies (H. Mamad 2021, Y. El Aissaoui 2016, and F. Zizi in 2011), and international ones. However, the development of inhibitors varies from one individual to another according to several criteria (genetic and non-genetic).